Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to determine how often and how likely patients are to develop
Type 2 Diabetes or high cholesterol/lipids when receiving dasatinib or nilotinib as therapy
for Chronic Myelogenous Leukemia (CML).